Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...
Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...
TipRanks Ranking Metrics: This 4-star analyst ranks #324 out of 11,984, with a 61.73% success rate and a 15.50% average return per rating. Investors tracking Gerberry’s calls may appreciate his ...
In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...
Zacks Investment Research on MSN
Investors heavily search Pfizer Inc. (PFE): Here is what you need to know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Pfizer (NYSE:PFE) reported positive topline Phase 2b results for its once monthly GLP-1 obesity candidate PF-3944. The drug, ...
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...
Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...
StockStory.org on MSN
Pfizer (NYSE:PFE) posts better-than-expected sales in Q4 CY2025
Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion ...
Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results